Breaking: Stifel Nicolaus Maintains $80.0 PT On Aerie Pharma (NASDAQ:AERI) Shares, Maintains Their Original “Buy” Rating

April 23, 2018 - By Marguerite Chambers

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 0.53, from 1.73 in 2017Q3. It dropped, as 23 investors sold Aerie Pharmaceuticals, Inc. shares while 48 reduced holdings. 21 funds opened positions while 64 raised stakes. 34.86 million shares or 1.29% more from 34.42 million shares in 2017Q3 were reported.

Teacher Retirement Systems Of Texas reported 10,334 shares stake. Creative Planning holds 3,600 shares or 0% of its portfolio. Kentucky-based Teachers Retirement System Of The State Of Kentucky has invested 0.04% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 593,086 were accumulated by Columbus Circle Investors. Barclays Public Limited Co, United Kingdom-based fund reported 8,805 shares. Goldman Sachs Inc reported 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Glenmede Com Na reported 714 shares. Atwood & Palmer holds 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 200 shares. Employees Retirement Association Of Colorado stated it has 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Deutsche Financial Bank Ag has 88,167 shares. Secor Cap Advsr L P has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 4,553 shares. 150 are owned by Manchester Mngmt Ltd Liability Company. 16,400 were reported by Gsa Cap Prtn Ltd Liability Partnership. Sg Americas Secs Lc holds 12,331 shares or 0.01% of its portfolio. Jennison Assoc Limited Liability Corporation holds 0.08% or 1.39 million shares in its portfolio.

Aerie Pharma (NASDAQ:AERI) Rating Reaffirmed

In analysts note sent to clients and investors on Tuesday, 2 January, The “Buy” rating of Aerie Pharma (NASDAQ:AERI) shares was maintained at Stifel Nicolaus, who now has a $80.0 PT on the stock. Stifel Nicolaus’s PT would suggest a possible upside of 48.15 % from the current price of the company.

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 0.53, from 1.73 in 2017Q3. It dropped, as 23 investors sold Aerie Pharmaceuticals, Inc. shares while 48 reduced holdings. 21 funds opened positions while 64 raised stakes. 34.86 million shares or 1.29% more from 34.42 million shares in 2017Q3 were reported.

Teacher Retirement Systems Of Texas reported 10,334 shares stake. Creative Planning holds 3,600 shares or 0% of its portfolio. Kentucky-based Teachers Retirement System Of The State Of Kentucky has invested 0.04% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 593,086 were accumulated by Columbus Circle Investors. Barclays Public Limited Co, United Kingdom-based fund reported 8,805 shares. Goldman Sachs Inc reported 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Glenmede Com Na reported 714 shares. Atwood & Palmer holds 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 200 shares. Employees Retirement Association Of Colorado stated it has 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Deutsche Financial Bank Ag has 88,167 shares. Secor Cap Advsr L P has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 4,553 shares. 150 are owned by Manchester Mngmt Ltd Liability Company. 16,400 were reported by Gsa Cap Prtn Ltd Liability Partnership. Sg Americas Secs Lc holds 12,331 shares or 0.01% of its portfolio. Jennison Assoc Limited Liability Corporation holds 0.08% or 1.39 million shares in its portfolio.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 8 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals has $100.0 highest and $69.0 lowest target. $84.38’s average target is 56.26% above currents $54 stock price. Aerie Pharmaceuticals had 11 analyst reports since October 24, 2017 according to SRatingsIntel. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Wednesday, February 28. Cantor Fitzgerald has “Buy” rating and $86.0 target. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, January 24. The firm earned “Buy” rating on Tuesday, January 2 by Stifel Nicolaus. H.C. Wainwright reinitiated the shares of AERI in report on Friday, February 16 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, November 16. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Thursday, March 1 by H.C. Wainwright. Cowen & Co maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Thursday, November 9 with “Buy” rating. Cantor Fitzgerald maintained the shares of AERI in report on Monday, December 18 with “Buy” rating. Mizuho maintained the shares of AERI in report on Thursday, March 29 with “Buy” rating.

The stock increased 0.65% or $0.35 during the last trading session, reaching $54. About 6,130 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 16.25% since April 23, 2017 and is uptrending. It has outperformed by 4.70% the S&P500.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on May, 1. They expect $-0.89 earnings per share, down 17.11 % or $0.13 from last year’s $-0.76 per share. After $-1.38 actual earnings per share reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -35.51 % EPS growth.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.13 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.